Sunday, June 26, 2016

Week in Review 25/16




Welcome and thanks for reading! In this review, I will gather together important and interesting news and events over the last week related to my portfolio holdings. In my week review, I put also together some interesting articles from other websites that caught my attention during the past week.

Friday, June 24, 2016

Recent Buy - Gilead Sciences Inc. (GILD)

Today on 24th June I Bought 20 shares of  Gilead Sciences Inc. at $ 79.89 per share plus commission.




Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company’s products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.


Sunday, June 19, 2016

Week in Review 24/16




Welcome and thanks for reading! In this review, I will gather together important and interesting news and events over the last week related to my portfolio holdings. In my week review, I put also together some interesting articles from other websites that caught my attention during the past week.

Friday, June 17, 2016

Recent Buy - Magna International Inc. (MGA)

16th June I Bought 50 shares of  Magna International Inc. at $ 38.33 per share plus commission.




Magna International Inc. develops, manufactures, engineers, supplies, and sells automotive products. It operates through North America, Europe, Asia, and Rest of World segments. The company offers body and chassis systems, and related engineering services; seating systems, including complete seating systems, seat structures and mechanisms, and foam and trim products; and powertrain systems, such as transmissions, driveline systems, fluid pressure and controls, metal forming solutions, and engineering services. It also provides vision systems comprising interior and exterior mirrors, actuators, door handle illumination products, headlamps and tail lamps, and small lighting products; and closure systems comprising door modules, power closure systems, engineered glass products, window systems, running boards and roof racks, latching systems, lighting systems, sealing systems, electronic features, handle assemblies, composite components, and hinges and rods. In addition, the company provides electronic systems, including driver assistance systems, secure connectivity products, head-up displays, and electronic controllers; exterior systems, such as fascia and trim products, front end modules, liftgate and exterior modules, active aerodynamics, and lightweight composites; and roof systems, including sliding folding and modular roofs, retractable hard tops, and soft tops. Further, it offers vehicle engineering and contract vehicle assembly services; fuel systems; engineering support services; and tooling and other products. The company was founded in 1957 and is headquartered in Aurora, Canada.

Sunday, June 12, 2016

Week in Review 23/16




Welcome and thanks for reading! In this review, I will gather together important and interesting news and events over the last week related to my portfolio holdings. In my week review, I put also together some interesting articles from other websites that caught my attention during the past week.

Thursday, June 9, 2016

Dividend Increase – Target Corporation (TGT)


Yesterday the Board of Directors of Target Corporation announced a quarterly dividend increase of from $0.56 to $0.60 per share that’s payable September 10, 2016 to holders of record August17 , 2016. This represents a 7.14% increase to regular quarterly dividends. With current price $68.35 (yesterdays open), this raise brings their dividend yield to 3.51%. 

The 3rd quarter dividend will be the company’s 196th consecutive dividend paid since October 1967 when the company became publicly held. With the increase announced today, 2016 is expected to be the 45th consecutive year in which Target has increased its annual dividend. 

Since I own 100 shares, this will increase my portfolio's projected annual net dividend income by $11.92.

That increase rises my YOC to 4.18%.

Click here to see my portfolio holdings.

You can follow the development of my dividends here.

Thanks for stopping by!
 

Wednesday, June 8, 2016

Dividend Income - May 2016

Again, one month passed and it is time to report my dividend income. In May 2016 my portfolio dividend income was as follows:

Annual dividend received from:

Tele2 B (TEL2-B) - €115.24 ($128.40) 


Quarterly dividends received from: 

AT&T Inc. (T) - €130.45 ($148.80)
Toronto-Dominion Bank (TD.TO) - €58.28 ($64.95)
Avance Gas Holding Ltd. (AVANCE) - €104.04 ($120.00)   
Kinder Morgan Inc. (KMI) - €22.09 ($25.01
ONEOK Inc. (OKE) - €27.19 ($30.75) 
Omega Healthcare Investors (OHI) - €50.35 ($57.00)
Eaton Corporation (ETN) - €15.23 ($17.10
HCP Inc. (HCP) - €51.61 ($57.50)
Royal Bank of Canada (RY.TO) - €66.93 ($76.80
Alerian MLP ETF (AMLP) - €107.15 ($120.00)
TAL International Group Inc. (TAL) - €40.49 ($45.00) 

Sunday, June 5, 2016

Week in Review 22/16




Welcome and thanks for reading! In this review, I will gather together important and interesting news and events over the last week related to my portfolio holdings. In my week review, I put also together some interesting articles from other websites that caught my attention during the past week.

You might also like